---
title: "AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299809900.md"
description: "AYTU BIOPHARMA reported FY2026 net revenue of $57.57M, a 13.3% decline from the prior year, with a net loss of ($14.25M) and diluted EPS of ($1.16). The company launched EXXUA (gepirone), generating $6.6M in initial sales, while divesting its Consumer Health business and winding down non-core programs. Management shifted resources to EXXUA commercialization, though it faces potential generic challenges to Adzenys."
datetime: "2026-09-22T20:25:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299809900.md)
  - [en](https://longbridge.com/en/news/299809900.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299809900.md)
generator: "portal-rs"
---

# AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary

AYTU BIOPHARMA, INC reported fiscal 2026 net revenue of $57.57M, down 13.3% from $66.38M a year earlier, and a net loss of ($14.25M) with diluted EPS of ($1.16) — results disclosed in its 10-K for the year ended 2026.

**Financial Highlights**

Metric

Current year

Prior year

YoY change

Revenue¹

$57.57M

$66.38M

(13.3%)

Net income²

($14.25M)

($13.56M)

(5.1%)

Diluted EPS³

($1.16)

($2.16)

46.3%

*¹ Reported as “Net revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted income per share”.*

**Business Highlights**

-   Launched EXXUA (gepirone) in FY2026, generating $6.6M in initial sales and representing the company’s strategic shift toward prescription CNS products.
-   Net revenue decline was partially offset by EXXUA’s launch as management redirected resources from pediatric and legacy ADHD products to EXXUA commercialization.
-   Completed divestiture of the Consumer Health business, wound down non-core clinical programs, and transitioned Adzenys/Cotempla manufacturing to a U.S. contract manufacturer.
-   Maintained product availability with no reported EXXUA or ADHD stock outages; faces potential generic challenge to Adzenys through Paragraph IV litigation.

Original SEC Filing: AYTU BIOPHARMA, INC \[ AYTU \] - 10-K - Sep. 22, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AYTU.US](https://longbridge.com/en/quote/AYTU.US.md)

## Related News & Research

- [Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales](https://longbridge.com/en/news/299809035.md)
- [AYTU: EXXUA launch drives growth in CNS therapeutics, with FY26 revenue at $66.4M](https://longbridge.com/en/news/299813775.md)
- [‘Watch That Cliff,’ Says Top Investor on Micron Stock](https://longbridge.com/en/news/300813618.md)
- [LIVE MARKETS-AI stock concentration nears past bubble peaks](https://longbridge.com/en/news/300813992.md)
- [ARK's Winton says each Starship launch could add $700 million a year](https://longbridge.com/en/news/300832406.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**